Costs of COPD in Sweden according to disease severity

Chest

Volumn 122, Issue 6, 2002, Pages 1994-2002

  Jansson, Sven Arne ^a   Andersson, Fredrik ^c   Borg, Sixten ^c   Ericsson, Åsa ^c   Jönsson, Elsy ^b   Lundbäck, Bo ^d  

^a SUNDERBY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

COPD; Cost of illness; Severity; Sweden

Indexed keywords

ANTIASTHMATIC AGENT;

ABSENTEEISM; ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISABILITY; DISEASE SEVERITY; EQUIPMENT; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MONEY; OUTCOMES RESEARCH; OUTPATIENT; OXYGEN THERAPY; PATIENT CARE; PENSION; PREVALENCE; PRIORITY JOURNAL; SWEDEN; TELEPHONE;

EID: 0036932480     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.122.6.1994     Document Type: Article

References (43)

1. Buist AS. Risk factors for COPD. Eur Respir Rev 1996; 6:253-258
2. Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking: 40 years observations on male British doctors. BMJ 1994; 149:1218-1226
3. Lundbäck B, Lindberg A, Lindström M, et al. Not fifteen but fifty percent of smokers develop COPD? Report from the Obstructive Lung Disease Studies in Northern Sweden. Respir Med 2002 (in press)
4. Silberman C, Lally CA, Lydick E. Determination of lifetime risk for development of COPD: A simplified lifetables approach using NHANES III and the NMFS. Eur Respir J 2000; 16(S32):12S
5. Bakke P, Baste V, Hanoa R, et al. Prevalence of obstructive lung disease in a general population: Relation to occupational title and exposure to some airborne agents. Thorax 1991; 46:863-870
6. Larsson L, Boethius G, Uddenfeldt M. Differences in utilisation of asthma drugs between two neighbouring Swedish provinces: Relation to prevalence of obstructive airway disease. Thorax 1994; 49:41-49
7. Isoaho R, Puolijoki H, Huhti E, et al. Prevalence of chronic obstructive pulmonary disease in elderly Finns. Respir Med 1994; 88:571-580
8. Curtis JR, Deyo RA, Hudson LD. Health-related quality of life among patients with chronic obstructive pulmonary disease. Thorax 1994; 49:162-170
9. Engström CP, Persson LO, Larsson S, et al. Reliability and validity of a Swedish version of the St. George's Respiratory Questionnaire. Eur Respir J 1998; 11:61-66
10. Sullivan SD, Ramsye SD, Lee TA. The economic burden of COPD. Chest 2000; 117:5S-9Ss
11. Rutten-Van Mölken MPMH, Postma MJ, Joore MA, et al. Current and future medical cost of asthma and chronic obstructive pulmonary disease in the Netherlands. Respir Med 1999; 93:779-787
12. Jacobsson L, Hertzman P, Löfdahl CG, et al. The economic impact of asthma and chronic pulmonary disease (COPD) in Sweden 1980 and 1991. Respir Med 2000; 94:247-255
13. Fletcher C, Peto R, Tinker R, et al. The Natural History of Chronic Bronchitis and Emphysema. Oxford, UK: Oxford University Press, 1976
14. Ward MM, Javitz HS, Smith WM, et al. Direct medical cost of chronic obstructive pulmonary disease in the USA. Respir Med 2000; 94:1123-1129
15. Wilson L, Devine EB, So K. Direct medical costs of chronic obstructive pulmonary disease: Chronic bronchitis and emphysema. Respir Med 2000; 94:204-213
16. Luce BR, Elixhauser A. Standards for Socioeconomic Evaluations of Health Care Products and Services. Berlin, Germany: Springer-Verlag, 1990
17. Rice DP. Estimating the cost of illness. Health Economics Series No. 6. Public Health Service. Washington DC: US Government Printing Office, 1996
18. Lundbäck B, Nyström L, Rosenhall L, et al. Obstructive lung disease in northern Sweden: Respiratory symptoms assessed in a postal survey. Eur Respir J 1991; 4:257-266
19. Lundbäck B, Stjernberg N, Nyström L, et al. Epidemiology of respiratory symptoms, lung function and important determinants: Report from the Northern Sweden Obstructive Lung Disease Project. Tuber Lung Dis 1994; 75:116-126
20. Lundbäck B. Asthma, Chronic Bronchitis and Respiratory Symptoms: Prevalence and Important Determinants. The Obstructive Lung Disease in Northern Sweden Study I. Umeå Univ Med Diss, New Series No. 387, ISBN 91-7174-825-3, 1993
21. Lundbäck B. Epidemiology of rhinitis and asthma. Clin Exp Allergy 1998; 28(S2):3-10
22. Rönmark E. Asthma Incidence, Remission and Risk Factors. The Obstructive Lung Disease in Northern Sweden Study II. Umeå Univ Med Diss, New Series No. 630, ISBN 91-7191-708-X, ISSN 0346-6612, 1999
23. Lindström M, Jönsson E, Larsson K, et al. Underdiagnosis of chronic obstructive pulmonary disease in Northern Sweden. Int J Tuberc Lung Dis 2002; 6:76-84
24. Lundbäck B, Rönmark E, Jönsson E, et al. 10 Year follow-up of the Obstructive Lung Disease in Northern Sweden study's (OLIN) first cohort. Am J Respir Crit Care Med 1999; 159:134A
25. British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997, 52(S5):1S-28S
26. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163:1256-1276
27. Evans C, Crawford B. Patient self-reports in pharmacoeconomic studies. Pharmacoeconomics 1999; 15:241-256
28. Revicki DA, Irwin D, Reblando J, et al. The accuracy of self-reported disability days. Med Care 1994; 32:401-404
29. Rutten-Van Mölken MPMH, Van Doorslaer EKA, Van Vliet RCJA. Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Econ 1994; 3:333-345
30. Andersson F, Nilsson B, Gundersen T. The effect on health-care costs of adding to conventional therapy for patients with congestive heart failure. BMJ Economics 1995; 8:125-135
31. FASS (Swedish Pharmacopoeia). Stockholm, Sweden: Linfo, 1999
32. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998; 13:1-7
33. Statistical Yearbook 1999. Stockholm, Sweden: Statistics Sweden, 1999
34. Hjort JSU. Computer Intensive Statistical Methods, Validation, Model, Selection, and Bootstrap. London, UK: Chapman and Hall, 1994
35. Hilleman DE, Dewan M, Malesker M, et al. Pharmaco-economic evaluation of COPD. Chest 2000; 118:1278-1282
36. Decramer M, Gosselink R, Troosters T, et al. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 1997; 10:417-423
37. Strauss MJ, Conrad D, Logerfo JP, et al. Cost and outcome of care for patients with chronic obstructive lung disease. Med Care 1986; 24:915-924
38. 1 as predictors of hospitalization and medication in the following 12 years due to respiratory disease. Eur Respir J 1989; 2:710-715
39. National Health Service Executive. Burdens of Disease: A Discussion Document. Leeds, UK: Department of Health, 1996
40. National Heart, Lung, and Blood Institute. Morbidity and Mortality: 1996 Chart Book on Cardiovascular, Lung and Blood Disease. Washington DC: National Institutes of Health, 1996
41. Swedish National Board of Social Insurance Statistikinformation Is-I 2000:002 and 2000:003. Stockholm: RFV, 2000
42. Rennard SI, Daughton DM. Smoking cessation. Chest 2000; 117:360-364
43. Parrott S, Godfrey C, Raw M, et al. Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Thorax 1998; 53(5S):1-38